Topoisomerase I expression correlates to response to neoadjuvant irinotecan-based chemoradiation in rectal cancer

Anti-Cancer Drugs

Volumn 20, Issue 6, 2009, Pages 519-524

  Horisberger, Karoline ^a   Erben, Philipp ^a   Muessle, Benjamin ^a   Woernle, Christoph ^a   Stroebel, Philipp ^b   Kaehler, Georg ^a   Wenz, Frederik ^a,b   Hochhaus, Andreas ^a,b   Post, Stefan ^a,b   Willeke, Frank ^a,c   Hofheinz, Ralf Dieter ^a,b  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c Chirurgische Klinik   (Germany)

Author keywords

Chemoradiotherapy; Irinotecan; Prediction; Rectal cancer; Thymidylate synthase; Topoisomerase I

Indexed keywords

CAPECITABINE; CETUXIMAB; DNA TOPOISOMERASE; IRINOTECAN; MESSENGER RNA; THYMIDYLATE SYNTHASE;

ARTICLE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CLINICAL ARTICLE; CONTROLLED STUDY; GENE EXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; RECTUM CANCER; RECTUM MUCOSA; TREATMENT RESPONSE; TUMOR BIOPSY;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOPSY; CAMPTOTHECIN; DNA TOPOISOMERASES, TYPE I; HUMANS; INTESTINAL MUCOSA; NEOADJUVANT THERAPY; NEOPLASM INVASIVENESS; PROSPECTIVE STUDIES; RECTAL NEOPLASMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; THYMIDYLATE SYNTHASE; TUMOR MARKERS, BIOLOGICAL;

EID: 67249152349     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/CAD.0b013e32832b53ff     Document Type: Article

References (38)

1. Sauer R, Becker H, Hohenberger W, Rodel C, Wittekind C, Fietkau R, et al. Preoperative versus postoperative chemoradiotherapy in rectal cancer. N Engl J Med 2004; 351:1731-1740. (Pubitemid 39383208)
2. Dworak O, Keilholz L, Hoffmann A. Pathological features of rectal cancer after preoperative radiochemotherapy. Int J Colorectal Dis 1997; 12:19-23. (Pubitemid 27138353)
3. Rödel C, Martus H, Papadoupolos T, Fuzesi L, Klimpfinger M, Fietkau R, et al. Prognostic significance of tumor regression after preoperative chemoradiotherapy in rectal cancer. J Clin Oncol 2005; 23:8688-8696. (Pubitemid 46211512)
4. Willeke F, Horisberger K, Kraus-Tiefenbacher U, Wenz F, Leitner A, Hochhaus A, et al. A phase II study of capecitabine and irinotecan in combination with concurrent pelvic radiotherapy (Caplri-RT) as neoadjuvant treatment of locally advanced rectal cancer. Br J Cancer 2007; 96:912-917. (Pubitemid 46452282)
5. Mehta VK, Cho C, Ford JM, Jambalos C, Poen J, Koong A, et al. Phase II trial of preoperative 3D conformal radiotherapy, protracted venous infusion 5-fluorouracil, and weekly CPT-11, followed by surgery for ultrasound-staged T3 rectal cancer. Int J Radiat Oncol Biol Phys 2003; 55:132-137. (Pubitemid 36020352)
6. Rödel C, Grabenbauer GG, Papadopoulos T, Hohenberger W, Schmoll HJ, Sauer R. Phase I/II trial of capecitabine, oxaliplatin, and radiation for rectal cancer. J Clin Oncol 2003; 21:3098-3104. (Pubitemid 46613485)
7. Kim IJ, Lim SB, Kang HC, Pyo HR, Choi YJ, Kim H, et al. Microarray gene expression profiling for predicting complete response to preoperative chemoradiotherapy in patients with advanced rectal cancer. Dis Colon Rectum 2007; 50:1-12. (Pubitemid 47472394)
8. Hoff PM, Ansari A, Batist G, Cox J, Kocha W, Kuperminc M, et al. Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. J Clin Oncol 2001; 19:2282-2292. (Pubitemid 32366981)
9. Miwa M, Ura M, Nishida M, Sawada N, Ishikawa T, Mori K, et al. Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur J Cancer 1998; 34:1274-1281. (Pubitemid 28342121)
10. Hardy LW, Finer-Moore JS, Montfort RS, Jones MO, Santi DV, Stroud RM. Atomic structure of thymidylate synthase: Target for rational drug design. Science 1987; 235:448-455. (Pubitemid 17009578)
11. Rougier P, Van Cutsem E, Bajetta E, Niederle N, Possinger K, Labianca R, et al. Randomised trial of irinotecan versus fluorouracil by continouous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet 1998; 352:1407-1412.
12. Slichenmyer WJ, Donehower RC. Recent clinical advances with camptothecin analogues. Cancer Treat Res 1995; 78:29-43.
13. Kirichenko AV, Rich TA. Radiation enhancement by 9-aminocamptothecin: the effect of fractionation and timing of administration. Int J Radiat Oncol Biol Phys 1999; 44:659-664. (Pubitemid 29258442)
14. Guichard S, Terret C, Hennebelle I, Lochon I, Chevreau P, Fretigny E, et al. CPT-11 converting carboxylesterase and Topoisomerase I activities in tumor and normal colon and liver tissues. Br J Cancer 1999; 80:364-370. (Pubitemid 29213186)
15. Salonga D, Danenberg KD, Johnson M, Metzger R, Groshen S, Tsao-Wei DD, et al. Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase. Clin Cancer Res 2000; 6:1322-1327. (Pubitemid 30226214)
16. Boonsong A, Curran S, McKay J, Cassidy J, Murray GI, McLeod HL. Topoisomerase I protein expression in primary colorectal cancer and lymph node metastases. Hum Pathol 2002; 33:1114-1119. (Pubitemid 35416709)
17. Paradiso A, Xu J, Mangia A, Chiriatti A, Simone G, Zito A, et al. Topoisomerase-I, thymidilate synthase primary tumor expression and clinical efficacy of 5-FU/CPT-11 chemotherapy in advanced colorectal cancer patients. Int J Cancer 2004; 111:252-258. (Pubitemid 38924703)
18. Hofheinz RD, Horisberger K, Woernle C, Wenz F, Kraus-Tiefenbacher U, Kähler G, et al. Phase I trial of cetuximab in combination with capecitabine, weekly irinotecan, and radiotherapy as neoadjuvant therapy for rectal cancer. Int J Radiat Oncol Biol Phys 2006; 66:1384-1390. (Pubitemid 44778934)
19. Mueller MC, Erben P, Saglio G, Gottardi E, Nyvold CG, Schenk T, et al. Harmonization of BCR-ABL mRNA quantification using a uniform multifunctional control plasmid in 37 international laboratories. Leukemia 2008; 22:96-102.
20. Braun MS, Richman SD, Quirke P, Daly C, Adlard JW, Elliott F, et al. Predictive biomarkers of chemotherapy efficacy in colorectal cancer: results from the UK MRC FOCUS trial. J Clin Oncol 2008; 26:2690-2698.
21. 2, Pavillard V, Charasson V, Laroche-Clary A, Soubeyran I, Robert J. Cellular parameters predictive of the clinical response of colorectal cancers to irinotecan. A preliminary study. Anticancer Res 2004; 24:579-586. (Pubitemid 38624992)
22. Wallin A, Svansik J, Holmlund B, Ferreud L, Sun XF. Anticancer effect of AN-38 on colon cancer cell lines with different metastatic potential. Oncol Rep 2008; 19:1493-1498.
23. Boothman DA, Fukunaga N, Wang M. Down-regulation of Topoisomerase I in mammalian cells following ionizing radiation. Cancer Res 1994; 54:4618-4626. (Pubitemid 24276484)
24. Liu LF. DNA topoisomerase poisons as antitumor drugs. Annu Rev Biochem 1989; 58:351-375. (Pubitemid 19172974)
25. Lansiaux A, Bras-Goncalves RA, Rosty C, Laurent-Puig P, Poupon MF, Bailly C. Topoisomerase I-DNA covalent complexes in human colorectal cancer xenografts with different p53 and microsatellite instability status: relation with their sensitivity to CTP-11. Anticancer Res 2001; 21:471-476. (Pubitemid 32267684)
26. Mao Y, Muller JR. Donw modulation of topoisomerase I affects DNA repair efficiency. DNA Repair 2003; 2:1115-1126. (Pubitemid 39662826)
27. Murren JR, Beidler DR, Cheng YC. Camptothecin resistance related to drug-induced down-regulation of Topoisomerase I and to steps occurring after the formation of protein-linked DNA breaks. Ann N Y Acad Sci 1996; 803:74-92. (Pubitemid 27057976)
28. Atkin GK, Daley FM, Bourne S, Glynne-Jones R, Northover JMA, Wilson GD. The impact of surgically induced ischaemia on protein levels in patients undergoing rectal cancer surgery. Br J Cancer 2006; 95:928-933. (Pubitemid 44498110)
29. Edler D, Hallstrom M, Johnston PG, Magnusson I, Ragnhammar P, Blomgren H. Thymidylate synthase expression: an independent prognostic factor for local recurrence, distant metastasis, disease-free and overall survival in rectal cancer. Clin Cancer Res 2000; 6:1378-1384. (Pubitemid 30226223)
30. Etienne MC, Chazal M, Laurent-Puig P, Magne N, Rosty C, Formento JL, et al. Prognostic value of tumoral thymidylate synthase and p53 in metastatic colorectal cancer patients receiving fluorouracil-based chemotherapy: phenotypic and genotypic analyses. J Clin Oncol 2002; 20:2832-2843. (Pubitemid 34651512)
31. Johnston PG, Benson AB 3rd, Catalano P, Rao MS, O'Dwyer PJ, Allegra CJ. Thymidylate synthase protein expression in primary colorectal cancer: lack of correlation with outcome and response to fluorouracil in metastatic disease sites. J Clin Oncol 2003; 21:815-819.
32. Glynne-Jones R, Anyamene N. Just how useful an endpoint is complete pathological response after neoadjuvant chemoradiation in rectal cancer. Int J Radiat Oncol Biol Phys 2006; 66:319-320. (Pubitemid 44332753)
33. Collette L, Bosset JF, den Dulk M, Nguyen F, Mineur L, Maingon P, et al. Patients with curative resection of cT3-4 rectal cancer after preoperative radiotherapy or radiochemotherapy: does anybody benefit from adjuvant fluorouracil-based chemotherapy? A trial of the European Organisation for Research and Treatment of Cancer Radiation Oncology Group. J Clin Oncol 2007; 25:4379-4386. (Pubitemid 350013843)
34. Fietkau R, Klautke G. Adjuvant chemotherapy following therapy of rectal cancer: the type of neoadjuvant therapy (chemoradiotherapy or radiotherapy) may be important for selection of patients. J Clin Oncol 2008; 26:507. (Pubitemid 351187742)
35. Liersch T, Langer C, Ghadimi BM, Kulle B, Aust DE, Baretton GB, et al. Lymph node status and TS gene expression are prognostic markers in stage II/III rectal cancer after neoadjuvant fluorouracil-based chemoradiotherapy. J Clin Oncol 2006; 24:4062-4068. (Pubitemid 46628475)
36. Quah HM, Chou JF, Gonen M, Shia J, Schrag D, Saltz LB, et al. Pathologic stage is most prognostic of disease-free survival in locally advanced rectal cancer patients after preoperative chemoradiation. Cancer 2008; 113:57-64. (Pubitemid 351976386)
37. Lièvre A, Bachet JB, Boige V, Cayre A, Le Corre D, Buc E, et al. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol 2008; 26:374-379. (Pubitemid 351171687)
38. Heinemann V, Stitzing S, Kirchner T, Boeck S, Jung A. Clinical relevance of EGFR- and KRAS-status in colorectal cancer patients treated with mononucleal antibodies directed against the EGFR. Cancer Treat Rev doi: 10.1016/j.ctrv.2008. 11.005 [Epub ahead of print]